New treatments

This page will list articles and news about new cancer treatments approved in Canada.

Health Canada approves TECENTRIQ® (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (April 2018)

Health Canada Approves RITUXAN® Subcutaneous Formulation for Canadians with Chronic Lymphocytic Leukemia (March 2018)

Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF® (trifluridine and tipiracil tablets) for metastatic colorectal cancer (March 2018)

Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE™ for the First-Line Treatment of Metastatic Breast Cancer (February 2018)

Health Canada Approves New Indication for ZYTIGA®* (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer (February 2018)

Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs) (February 2018)

Tagrisso® (osimertinib) receives full Health Canada approval for targeted treatment of non-small cell lung cancer (January 2018)